Acute effect of sildenafl is maintained in pulmonary arterial hypertension patients chronically treated with bosentan

International Heart Journal

Volumn 52, Issue 4, 2011, Pages 233-239

  Hatano, Masaru ^a   Yao, Atsushi ^a   Kinugawa, Koichiro ^a   Hirata, Yasunobu ^a   Nagai, Ryozo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Bosentan; Cardiac output; Pulmonary arterial hypertension; Pulmonary vascular resistance; Sildenafl

Indexed keywords

BOSENTAN; SILDENAFIL; ANTIHYPERTENSIVE AGENT; PHOSPHODIESTERASE V INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONAMIDE; SULFONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HEART INDEX; HUMAN; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG COMBINATION; FOLLOW UP; LUNG WEDGE PRESSURE; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; PULMONARY ARTERY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VASCULAR RESISTANCE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PROSPECTIVE STUDIES; PULMONARY ARTERY; PULMONARY WEDGE PRESSURE; PURINES; SULFONAMIDES; SULFONES; TREATMENT OUTCOME; VASCULAR RESISTANCE; YOUNG ADULT;

EID: 80051629036     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.52.233     Document Type: Article

References (34)

1. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S78-S84. (Review)
2. Galiè N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosen-tan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-2100.
3. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafl therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-2903.
4. Gupta M, Kovar A, Meibohm B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol 2005; 45: 987-1003. (Review)
5. Treiber A, Schneiter R, Häusler S, Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cy-closporin A, rifampicin, and sildenafl. Drug Metab Dispos 2007; 35: 1400-1407.
6. Burgess G, Hoogkamer H, Collings L, Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafl. Eur J Clin Pharmacol 2008; 64: 43-50.
7. Dingemanse J, van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacoki-net 2004; 43: 1089-1115. (Review)
8. Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR. Bosentan decreases the plasma concentration of sildenafil when copre-scribed in pulmonary hypertension. Br J Clin Pharmacol 2005; 60: 107-112.
9. Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Nied-ermeyer J. Combination therapy with bosentan and sildenafl in idiopathic pulmonary arterial hypertension. Eur Respir J 2004; 24: 1007-1010.
10. Lunze K, Gilbert N, Mebus S, et al. First experience with an oral combination therapy using bosentan and sildenafl for pulmonary arterial hypertension. Eur J Clin Invest 2006; 36: 32-38.
11. Gruenig E, Michelakis E, Vachiéry JL, et al. Acute hemodynamic effects of single-dose sildenafl when added to established bosen-tan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. J Clin Pharmacol 2009; 49: 1343-1352.
12. Eerkes A, Addison T, Naidong W. Simultaneous assay of sildenafl and desmethylsildenafl in human plasma using liquid chromatog-raphy-tandem mass spectrometry on silica column with aqueous-organic mobile phase. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 768: 277-284.
13. Hyland R, Roe EG, Jones BC, Smith DA. Identifcation of the cy-tochrome P450 enzymes involved in the N-demethylation of silde-nafl. Br J Clin Pharmacol 2001; 51: 239-248.
14. Wilkins MR, Wharton J, Grimminger F, Ghofrani HA. Phosphodi-esterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J 2008; 32: 198-209.
15. Weitzberg E, Ahlborg G, Lundberg JM. Differences in vascular effects and removal of endothelin-1 in human lung, brain, and skeletal muscle. Clin Physiol 1993; 13: 653-662.
16. Pernow J, Kaijser L, Lundberg JM, Ahlborg G. Comparable potent coronary constrictor effects of endothelin-1 and big endothe-lin-1 in humans. Circulation 1996; 94: 2077-2082.
17. Pernow J, Hemsén A, Lundberg JM, Nowak J, Kaijser L. Potent vasoconstrictor effects and clearance of endothelin in the human forearm. Acta Physiol Scand 1991; 141: 319-324.
18. Cardillo C, Kilcoyne CM, Waclawiw M, Cannon RO 3rd, Panza JA. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 1999; 33: 753-758.
19. Verhaar MC, Strachan FE, Newby DE, et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998; 97: 752-756.
20. Cardillo C, Campia U, Iantorno M, Panza JA. Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. Hypertension 2004; 43: 36-40.
21. Nohria A, Garrett L, Johnson W, Kinlay S, Ganz P, Creager MA. Endothelin-1 and vascular tone in subjects with atherogenic risk factors. Hypertension 2003; 42: 43-48.
22. Cardillo C, Kilcoyne CM, Cannon RO 3rd, Panza JA. Increased activity of endogenous endothelin in patients with hypercholester-olemia. J Am Coll Cardiol 2000; 36: 1483-1488.
23. Taddei S, Virdis A, Ghiadoni L, Sudano I, Notari M, Salvetti A. Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. Circulation 1999; 100: 1680-1683.
24. Böhm F, Johansson BL, Hedin U, Alving K, Pernow J. Enhanced vasoconstrictor effect of big endothelin-1 in patients with atherosclerosis: relation to conversion to endothelin-1. Atherosclerosis 2002; 160: 215-222.
25. Kinlay S, Behrendt D, Wainstein M, et al. Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation 2001; 104: 1114-1118.
26. Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 2002; 106: 1783-1787.
27. Cella G, Vianello F, Cozzi F, et al. Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases. J Rheu-matol 2009; 36: 760-767.
28. Sfkakis P P, Papamichael C, Stamatelopoulos KS, et al. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum 2007; 56: 1985-1993.
29. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fbrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360: 895-900.
30. Voswinckel R, Reichenberger F, Enke B, et al. Acute effects of the combination of sildenafil and inhaled treprostinil on haemody-namics and gas exchange in pulmonary hypertension. Pulm Pharmacol Ther 2008; 21: 824-832.
31. Ziolo MT, Lewandowski SJ, Smith JM, Romano FD, Wahler GM. Inhibition of cyclic GMP hydrolysis with zaprinast reduces basal and cyclic AMP-elevated L-type calcium current in guinea-pig ventricular myocytes. Br J Pharmacol 2003; 138: 986-994.
32. Wang H, Kohr MJ, Traynham CJ, Ziolo MT. Phosphodiesterase 5 restricts NOS3/Soluble guanylate cyclase signaling to L-type Ca2+ current in cardiac myocytes. J Mol Cell Cardiol 2009; 47: 304-314.
33. Nagendran J, Archer SL, Soliman D, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007; 116: 238-248.
34. Qvigstad E, Moltzau LR, Aronsen JM, et al. Natriuretic peptides increase beta1-adrenoceptor signalling in failing hearts through phosphodiesterase 3 inhibition. Cardiovasc Res 2010; 85: 763-772.